NCT06687434

Brief Summary

The goal of this study is to compare qualitative meal-size estimation to accurate carb counting in adolescents with Type One Diabetes using all available AID (Automated Insulin Delivery) systems. We will compare glucose control parameters and patient related outcome measures between the groups. 120 children and adolescents with type 1 Diabetes who begin using AID system will be randomly assigned to one of two groups: simplified qualitative meal size estimation or accurate carb counting. The study will last 6 months, with an additional optional follow up points at 12 and 24 months. In the first visit all patients will receive nutrition guidance from the dietitian. In the accurate carb counting group, participants will use precise carb counting to manage their meals. In the simplified qualitative meal-size estimation group, participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment. During the study, the dietitian will evaluate the insulin-to-carb ratio and meal estimation at least once in the first two weeks. Follow-up visits will be scheduled at 4-6 weeks, 3, and 6 months after the study's initiation. At each visit participants will upload their data from their AID systems. Evaluation of their diabetes control will be made and an assessment regarding the carbohydrates calculation method. Digital questionnaires assessing diabetes distress, disordered eating behaviors, dietary regimen, and eating patterns will be provided at the beginning of the study and after 6 months, with an additional optional follow-up points that will be held at 12 and 24 months after the study's initiation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
20mo left

Started Dec 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Dec 2024Dec 2027

First Submitted

Initial submission to the registry

October 21, 2024

Completed
23 days until next milestone

First Posted

Study publicly available on registry

November 13, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

December 15, 2024

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2027

Last Updated

May 20, 2025

Status Verified

October 1, 2024

Enrollment Period

2.9 years

First QC Date

October 21, 2024

Last Update Submit

May 15, 2025

Conditions

Keywords

Automated insulin delivery systemcarb counting

Outcome Measures

Primary Outcomes (5)

  • Percentage of time in target range (70-18mg/dl)

    Screening, after 4-6 weeks, after 3 months and after 6 months

  • Hemoglobin A1C

    Screening, after 4-6 weeks, after 3 months and after 6 months

  • Percentage Continuous glucose monitoting usage

    Screening, after 4-6 weeks, after 3 months and after 6 months

  • Number of Episodes of severe hypoglycemia

    Screening, after 4-6 weeks, after 3 months and after 6 months

  • Number of episodes of Diabetic Ketoacidosis

    Screening, after 4-6 weeks, after 3 months and after 6 months

Secondary Outcomes (11)

  • Total daily insulin dose

    at screening, after 4-6 weeks, after 3 months and after 6 months.

  • basal insulin dose

    at screening, after 4-6 weeks, after 3 months and after 6 months.

  • Number of manual boluses per day

    at screening, after 4-6 weeks, after 3 months and after 6 months.

  • Number of announced meals per day

    at screening, after 4-6 weeks, after 3 months and after 6 months.

  • Daily carbohydrates input

    at screening, after 4-6 weeks, after 3 months and after 6 months.

  • +6 more secondary outcomes

Study Arms (2)

Accurate carb counting

EXPERIMENTAL

Participants will use precise carb counting to manage their meals

Behavioral: accurate carb counting

Simplified qualitative meal-size estimation

EXPERIMENTAL

Participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian assessment.

Behavioral: Simplified qualitative meal size estimation

Interventions

Participants will use precise carb counting to manage their meals

Accurate carb counting

participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.

Simplified qualitative meal-size estimation

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • T1D- diagnosed
  • Age 6-18 years
  • Treated with insulin (multiple daily injections or pump) and intending to initiate treatment with AID systems

You may not qualify if:

  • Non-T1D
  • Unstable medical conditions (other than diabetes) that may impact weight or diabetes management (as severe psychiatric disorders, various syndromes)
  • Use of medications that may impact weight or diabetes management (as use of steroids for an extended period of time. use of GLP-1)
  • Inability to understand the information, material and questionnaires of the study -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Schneider Children's Medical Center

Petah Tikva, 4920235, Israel

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Michal Gilon Keren, Phd

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 21, 2024

First Posted

November 13, 2024

Study Start

December 15, 2024

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

December 15, 2027

Last Updated

May 20, 2025

Record last verified: 2024-10

Locations